OBI Phase III trial shows 40.5% fewer 30-day surgical site infections

OBI’s LANTERN Phase III study met its primary endpoint, with a 40.5% reduction in 30-day surgical site infections after adding nasal photodisinfection to standard care. The report says analyses supported the result and that the intervention showed a strong safety profile.